Anavex down after neurological disorder drug fails to meet one of the main goals

Anavex Life Sciences

02/01/2024 13:55

** Shares of drug developer Anavex Life Sciences  AVXL.O 
fall 33% to $6.24 premarket
    ** Company says its experimental drug to treat a rare
neurodevelopmental disease, Rett syndrome, in pediatric patients
did not meet one of the main goals in a mid- to late-stage study
    ** The drug failed to show statistically significant
improvement on a scale used to measure symptom severity,
treatment response, when compared to placebo
    ** Company is also studying the drug to treat other
neurodevelopmental disorders such as Fragile X syndrome
    ** Rett syndrome occurs almost exclusively in girls and
leads to severe impairments in their ability to speak, walk, eat
and even breathe easily


 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))